This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, oncology fellows, oncology nurses, internists, and other physicians, physicians-in-training, and healthcare professionals involved in and/or interested in lymphoma, myeloma, related plasma cell disorders, and in the special session of 2010, acute lymphoblastic leukemia.
Educational Objectives - Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and related diseases
- Discuss the role of the microenvironment in the development and disease progression of chronic lymphocytic leukemia and follicular lymphoma
- Evaluate how the disease risk and age of a patient determines optimal management and the course of therapy for lymphoma
- Describe the biology, management, and current treatment options of myeloma and lymphoma for front-line, salvage, and maintenance therapy, as well as therapeutic strategies to overcome relapsed/refractory disease
- Evaluate the feasibility of chemotherapy, radioimmunotherapy, targeted therapy, and transplantation as treatment options for various stages of indolent lymphoma
- Debate whether autologous or allogeneic stem cell transplantation is appropriate for management of mantle cell lymphoma
- Employ current and novel strategies to improve diagnosis and treatment outcomes in aggressive non-Hodgkin s lymphomas
- Determine whether specific subtypes of aggressive NHL should be treated
in the same manner
- Positively impact patient outcomes by assimilating diagnostic, prognostic, and molecular approaches toward optimal stratification for current and novel treatment options in acute lymphoblastic leukemia.
